22nd Century Group (XXII) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
1 Feb, 2026Executive summary
Net revenues for Q2 2024 were $7.95M, up 22.8% sequentially but down 1.3% year-over-year, with gross profit turning positive at $0.6M from a prior loss.
Operating expenses dropped 76% to $2.62M, and net loss from continuing operations improved to $2.2M from $13.7M year-over-year.
The company shifted focus from cost containment to growth, rebuilding the executive team and emphasizing both branded and contract manufacturing.
Substantial doubt remains about the ability to continue as a going concern due to recurring losses and low cash.
Emphasis on relaunching and rebranding the VLN low-nicotine cigarette product to drive future growth.
Financial highlights
Q2 2024 net revenues were $7.95M, gross profit $0.6M (7.2% margin), and operating loss $2.0M, all showing significant improvement year-over-year.
Operating expenses fell to $2.6M in Q2 2024 from $11.1M in Q2 2023, reflecting cost reduction initiatives.
Cash used in operations for six months was $6.97M, a significant reduction from $37.33M in 2023.
Net total debt reduced to $7.0M as of June 30, 2024, from $13.3M at year-end 2023.
Cash and cash equivalents at June 30, 2024, were $1.28M; working capital deficit improved to ($2.25M).
Outlook and guidance
Targeting net income and cash-positive operations by Q1 2025, with revenue growth expected from new contract manufacturing volumes in H2 2024.
Management is evaluating further cost reductions and financing strategies, including asset sales and new securities issuance.
No assurance of raising sufficient capital; may need to liquidate assets or seek bankruptcy protection if unsuccessful.
Latest events from 22nd Century Group
- Low-nicotine cigarettes gain retail traction, targeting break-even and growth with no direct rivals.XXII
17th Annual LD Micro Main Event Conference17 Jan 2026 - Q3 2024 revenue dropped 24.5% with ongoing losses, but net debt and cost structure improved.XXII
Q3 202414 Jan 2026 - Key votes include a reverse split, preferred stock, warrant changes, and a new offering.XXII
Proxy Filing30 Dec 2025 - VLN relaunch, FDA compliance, and CMO focus drive 2025 growth after 2024 turnaround.XXII
Q4 202426 Dec 2025 - Relaunching low-nicotine brands, expanding retail reach, and targeting profitability by Q4 2025.XXII
Emerging Growth Conference26 Dec 2025 - Special meeting seeks approval for reverse split, anti-dilution terms, and new capital offering.XXII
Proxy Filing19 Dec 2025 - Resale of 1.4M shares enables debt settlement for a tobacco innovator with FDA-authorized VLN products.XXII
Registration Filing16 Dec 2025 - Registering 104,124 shares for resale, with no proceeds to the company and ongoing financial risks.XXII
Registration Filing16 Dec 2025 - Registering 93.6M shares for resale; proceeds only from warrant exercises; faces losses and regulatory risks.XXII
Registration Filing16 Dec 2025